Tri-Pharma, Inc.
Kennesaw, GA
- UEI
- P2EDVGEMBDB3
- CAGE
- 5UXG1
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 975 Cobb Pl Blvd NW Ste 118, Kennesaw, GA 30144, USA
- Website
- tri-pharma.com
- Founded
- 2009
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 51 Wholesale Trade – Nondurable Goods
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $168,425 |
| FY2025 | $15,500 |
| FY2024 | $150,207 |
| FY2023 | $60,992 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Health Agency | $168,425 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| CT contrast | Defense Health Agency | $168,425 | |
| TRI-pharma, INC.:1307949 [25-002643] | NIH Clinical Center | $15,500 | |
| Sandostatin | Veterans Integrated Service Network 5 (VHA) | $74,190 | |
| Pharm - rydapt 25 MG SGC 4X28 | Veterans Integrated Service Network 20 (VHA) | $61,142 | |
| TRI-pharma, INC.:1307949 [24-000796] | NIH Clinical Center | $14,875 |
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Tri-Pharma, Inc., doing business as Tri-Pharma Inc., is a minority-owned, Hispanic American-owned small disadvantaged business and Subchapter S corporation headquartered in Kennesaw, Georgia that supplies pharmaceutical products and medical supplies to federal healthcare agencies as a prime contractor. All 102 recent awards are prime contracts; the vendor operates exclusively in pharmaceutical wholesale and medical supply distribution, with no subcontracting footprint across the federal government and no participation in larger contract vehicles or IDVs.
Tri-Pharma's capability portfolio centers on specialty pharmaceutical wholesale distribution (67 awards classified under Pharmaceutical Preparation Manufacturing NAICS) and medical supplies and surgical equipment (26 awards under Medical and Surgical Instruments, Equipment, and Supplies PSC). Representative recent work includes a $168,425 purchase order from the Defense Health Agency for CT contrast media awarded June 15, 2026 with performance at Camp Lejeune, North Carolina; a $15,500 delivery order from the NIH Clinical Center for SANDOSTATIN, RYDAPT, fludarabine, ranitidine, and personal protective equipment (N95 masks, surgical masks, disinfectant wipes) awarded December 10, 2024; and a $74,190 Total Small Business set-aside purchase order from the Department of Veterans Affairs Veterans Integrated Service Network 5 for SANDOSTATIN awarded March 1, 2024. The vendor has supplied pharmaceutical and medical products to the Department of Veterans Affairs, Indian Health Service, Department of Health and Human Services, and Department of the Army, predominantly through firm-fixed-price purchase orders with no set-aside designation in recent years.
Customer concentration is heavily weighted toward the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 15 (21 awards, $9 million combined potential value), which accounts for 57% of the vendor's combined potential-value share. The top five customer entities account for 73% of award count and 78% of combined potential value. The Department of Health and Human Services Indian Health Service (19 awards, $400 thousand) and the NIH Clinical Center (14 awards, $492 thousand) represent secondary volume customers, followed by multiple other VA VISNs and Indian Health Service facilities. The vendor's customer base spans 21 distinct federal agencies, but the portfolio is dominated by VA and HHS healthcare operations.
Activity has been uneven over the past five years — one award in 2021, five in 2022, four in 2023, two in 2024, and one in 2026 — with combined potential value of $15.8 million and combined obligated dollars of $15.6 million across all 102 awards. The most recent award closed on June 15, 2026. No recompete cliff data is provided in the source.
Quick answers
Is Tri-Pharma, Inc. registered in SAM.gov?
Yes. Tri-Pharma, Inc.'s SAM.gov registration is active through July 14, 2027.
How much has Tri-Pharma, Inc. received in federal contracts?
Federal contracts obligated $15,500 to Tri-Pharma, Inc. in fiscal year 2025 and $395,124 in fiscal years 2023 through 2027.
What is Tri-Pharma, Inc.'s most recent federal award?
Tri-Pharma, Inc.'s most recent federal contract award is CT contrast (HT940626PE073), from Defense Health Agency, on June 15, 2026.
On GovTribe
See Tri-Pharma, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors